Ovarian cancer molecular pathology
- 23 June 2012
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 31 (3-4) , 713-732
Abstract
Ovarian cancer (OVC) is the fourth leading cause of cancer mortality among women in Europe and the United States. Its early detection is difficult due to the lack of specificity of clinical symptoms. Unfortunately, late diagnosis is a major contributor to the poor survival rates for OVC, which can be attributed to the lack of specific sets of markers. Aside from patients sharing a strong family history of ovarian and breast cancer, including the BRCA1 and BRCA2 tumor suppressor genes mutations, the most used biomarker is the Cancer-antigen 125 (CA-125). CA-125 has a sensitivity of 80 % and a specificity of 97 % in epithelial cancer (stage III or IV). However, its sensitivity is 30 % in stage I cancer, as its increase is linked to several physiological phenomena and benign situations. CA-125 is particularly useful for at-risk population diagnosis and to assess response to treatment. It is clear that alone, CA-125 is inadequate as a biomarker for OVC diagnosis. There is an unmet need to identify additional biomarkers. Novel and more sensitive proteomic strategies such as MALDI mass spectrometry imaging studies are well suited to identify better markers for both diagnosis and prognosis. In the present review, we will focus on such proteomic strategies in regards to OVC signaling pathways, OVC development and escape from the immune response.Keywords
This publication has 192 references indexed in Scilit:
- Overexpression of the β Subunit of Human Chorionic Gonadotropin Promotes the Transformation of Human Ovarian Epithelial Cells and Ovarian TumorigenesisThe American Journal of Pathology, 2011
- The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signallingEMBO Molecular Medicine, 2011
- Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialCancer, 2011
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K SignalingCancer Cell, 2009
- MEKK3 expression correlates with nuclear factor κ B activity and with expression of antiapoptotic genes in serous ovarian carcinomaCancer, 2009
- Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progressionClinical & Experimental Metastasis, 2008
- Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomasProteomics – Clinical Applications, 2008
- Clinical and biological significance of HLA-G expression in ovarian cancerSeminars in Cancer Biology, 2007
- Neutrophil gelatinase‐associated lipocalin (NGAL) an early‐screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor‐induced epithelio‐mesenchymal transitionInternational Journal of Cancer, 2007
- NF‐κB and cancer: Mechanisms and targetsMolecular Carcinogenesis, 2006